The adjustment in price target by RBC Capital, while maintaining an Outperform rating, suggests a continued positive outlook on CVS Health but with a slightly moderated growth expectation. This could lead to a neutral short-term impact on the stock as the market digests the minor adjustment in valuation expectations.